<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963209</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000650376</org_study_id>
    <secondary_id>CHUV-CEPO-TM</secondary_id>
    <secondary_id>EU-20973</secondary_id>
    <nct_id>NCT00963209</nct_id>
  </id_info>
  <brief_title>Tamoxifen Citrate in Patients With Breast Cancer</brief_title>
  <official_title>Tamoxifen Metabolism and the Impact of Tamoxifen Dose on the Level of the Active Metabolites in Endocrine Sensitive Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can promote growth of endocrine sensitive breast cancer cells. Endocrine
      therapy with tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the
      tumor cells. Pharmacokinetics and -genomics can have an impact on the efficacy of the
      treatment.

      PURPOSE: This phase III trial is studying blood samples to see if the level of active
      metabolites of tamoxifen can be improved in patients with breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine how the increase of tamoxifen citrate dose influences the level of its
           major metabolites in patients with hormone-sensitive breast cancer.

      Secondary

        -  To characterize the population pharmacokinetic profile

        -  To investigate the role of the other CYPs

        -  To assess the relation between clinical symptoms and CYP2D6 genotypes and/or active
           metabolites levels

        -  To explore the correlation between genotypes/metabolites levels and clinical outcomes in
           terms of tumor relapse.

        -  To assess the feasibility, efficacy, and safety of concentration-guided adjustment of
           tamoxifen citrate dosage.

        -  To conduct other exploratory analysis based on the eventual new data coming up in the
           future.

      OUTLINE: Patients receive oral tamoxifen citrate (at a dose of 40 mg/day) daily for 4 months
      in the absence of disease progression or unacceptable toxicity.

      Blood samples are collected for PK, genotyping, phenotyping, and further analysis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of CYP2D6 genotype and determination of plasma concentrations of tamoxifen citrate and its metabolites (N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen and endoxifen) under the 20 mg daily and 40 mg daily schedules</measure>
    <time_frame>Jan 2013</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients' characteristics</measure>
    <time_frame>prospectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor characteristics</measure>
    <time_frame>prospectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer treatments history</measure>
    <time_frame>prospectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYP3A4 (phenotype), and possibly other cytochromes involved in the metabolism and transport of drugs</measure>
    <time_frame>prospectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of drug intake (date of tx initiation, current dosage and frequency, time of last intake) along with patient-reported adherence, assessed by questionnaire</measure>
    <time_frame>prospectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medication</measure>
    <time_frame>prospectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and quantitation of clinical symptoms</measure>
    <time_frame>prospectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection and classification of general comorbidities and side effects according to NCI-CTC v3.0</measure>
    <time_frame>prospectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of tumor relapse during the observation period of the study</measure>
    <time_frame>prospectively</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <arm_group_label>Tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Tamoxifen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of breast cancer

               -  Hormone-sensitive breast cancer defined as &gt; 10% estrogen receptor and/or &gt; 10%
                  progesterone receptor positivity by immunohistochemistry

          -  Receiving treatment with tamoxifen citrate and must be eligible for exposure to higher
             doses

        PATIENT CHARACTERISTICS:

          -  No history of deep venous thrombosis or pulmonary embolism

          -  No history of endometrial carcinoma

          -  No known history of vaginal bleeding, endometriosis, endometrial hyperplasia,
             endometrial hypertrophy, and/or polyps

          -  Not pregnant or nursing

          -  No contraindication to tamoxifen citrate treatment

          -  No known allergy to midazolam or dextromethorphan

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khalil Zaman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpitaux Universitaire de Genève</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Bodmer, MD</last_name>
      <phone>41 22 382 40 14</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalil Zaman, MD</last_name>
      <phone>41-21-314-0168</phone>
      <email>Khalil.Zaman@chuv.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2009</study_first_submitted>
  <study_first_submitted_qc>August 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2009</study_first_posted>
  <last_update_submitted>July 31, 2013</last_update_submitted>
  <last_update_submitted_qc>July 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Dr K. Zaman</investigator_full_name>
    <investigator_title>Médecin associé</investigator_title>
  </responsible_party>
  <keyword>endocrine sensitive</keyword>
  <keyword>breast cancer</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>genotyping</keyword>
  <keyword>phenotyping</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Endoxifen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

